The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer D-MNA and Teverelix collectively represent ~$8 billion in potential market opportunity PHILADELPHIA, PA / ACCESS Newswire / September 24, 2025 / Medicus Pharma Ltd. (NASDAQ:MD ...